EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Advancing Drug Discovery with AI: Machine and Deep Learning Strategies for Target Identification and Precision Nanomedicine

Ananya Chakraborty, Amol D Gholap iD, Pankaj R Khuspe, Gowri Sundaram, Thomas J Webster iD, Mohammad Khalid, Muhammad Salahuddin Haris iD, Md Faiyazuddin iD

International Journal of Nanomedicine · 2026-06 · Volume 21 · 1-62

DOI: 10.2147/ijn.s600651 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-06. Verfasst von Ananya Chakraborty und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, Haringhata, Nadia, West Bengal, 741249, India. Hauptthemen laut MEDLINE: Deep Learning, Drug Discovery, Nanomedicine, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of machine learning (ML) and deep learning (DL) into drug discovery and target identification has catalyzed a paradigm shift in pharmaceutical research, enhancing efficiency and translational potential for nano-enabled therapeutics. ML models have demonstrated up to 85% accuracy in predicting drug-target interactions, whereas DL frameworks, such as convolutional neural networks (CNNs), graph neural networks (GNNs), and transformer architectures, can improve molecular property predictions by 40%. AI-driven drug discovery workflows have curtailed drug candidate attrition rates by up to 30% and accelerated discovery timelines by 20%-40%, accentuating their rising industrial and clinical impact. This critical review evaluates the transformative roles of ML and DL in the drug discovery pipeline, emphasizing their capacity to accelerate development timelines and advance precision nano medicine. We analyzed predictive modelling techniques, including quantitative structure-activity relationship (QSAR) and absorption, distribution, metabolism, and excretion (ADME) predictions, which streamline the identification of viable drug candidates, including nanocarrier-enabled drug systems. Virtual screening and bioactivity prediction further refine candidate prioritization, whereas target identification and validation leverage protein-ligand interaction modelling and biological pathway analysis to ensure therapeutic specificity. Additionally, we discuss the profound impact of DL on medical image analysis, genomic data interpretation, and protein structure prediction (PSP), which collectively advance structural bioinformatics and enable optimized targeted nano medicine. By synergizing ML and DL, multi-modal data fusion, explainable artificial intelligence (XAI), and nanotechnology-driven datasets, the drug discovery process is evolving into a more efficient, predictive, and patient-centric endeavor, paving the way for ground-breaking therapies and improved clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep LearningDrug DiscoveryNanomedicinePrecision MedicinePredictive Learning ModelsHumansGraph Neural NetworksQuantitative Structure-Activity Relationship

Stichwörter der Autor:innen

deep learningdrug discoverydrug targetinggenomicsmachine learningprecision nanomedicinepredictive modellingvirtual screening

Autor:innen und Institutionen

  • Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, Haringhata, Nadia, West Bengal, 741249, India.
  • Department of Pharmaceutics, St. John Institute of Pharmacy and Research, Palghar, Maharashtra, 401404, India.
  • Department of Pharmaceutics, Shriram Shikshan Sanstha's College of Pharmacy, Paniv, Solapur, Maharashtra, 413113, India.
  • PG & Research Department of Physics, Cauvery College for Women (Autonomous), Tiruchirappalli, Tamil Nadu, India.
  • School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, People's Republic of China.
  • Program in Materials, Universidade Federal do Piauí, Teresina, Brazil.

ORCID-Profile: Amol D Gholap, Thomas J Webster, Muhammad Salahuddin Haris, Md Faiyazuddin

Zitieren

APA

Chakraborty, A., Gholap, A. D., Khuspe, P. R., Sundaram, G., Webster, T. J., Khalid, M., Haris, M. S., & Faiyazuddin, M. (2026). Advancing Drug Discovery with AI: Machine and Deep Learning Strategies for Target Identification and Precision Nanomedicine. International Journal of Nanomedicine, Volume 21, 1-62. https://doi.org/10.2147/ijn.s600651

Vancouver

Chakraborty A, Gholap AD, Khuspe PR, Sundaram G, Webster TJ, Khalid M, et al. Advancing Drug Discovery with AI: Machine and Deep Learning Strategies for Target Identification and Precision Nanomedicine. International Journal of Nanomedicine. 2026;Volume 21:1-62. doi:10.2147/ijn.s600651

BibTeX
@article{Chakraborty2026,
  author = {Chakraborty, Ananya and Gholap, Amol D and Khuspe, Pankaj R and Sundaram, Gowri and Webster, Thomas J and Khalid, Mohammad and Haris, Muhammad Salahuddin and Faiyazuddin, Md},
  title = {Advancing Drug Discovery with AI: Machine and Deep Learning Strategies for Target Identification and Precision Nanomedicine},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  volume = {Volume 21},
  pages = {1--62},
  doi = {10.2147/ijn.s600651}
}
Kostenlos starten →